Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of GFH276 in RAS-mutant advanced solid tumors
CTR20253687Phase 2Active
- Sponsor
- GenFleet Therapeutics
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GFH276 in Nonhematologic neoplasms, sponsored by GenFleet Therapeutics. Primary endpoints: Incidence and severity of adverse events and serious adverse events; changes in vital signs, electrocardiogram, and laboratory tests, Dose-limiting toxicity event rate and 1 more. Started Sep 2025; status: active.
02
Drugs
GFH276
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20253687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253687.